Search Results

You are looking at 1 - 2 of 2 items for

  • Author: L A Liotta x
  • Refine by access: All content x
Clear All Modify Search
T P Conrads National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by T P Conrads in
Google Scholar
PubMed
Close
,
V A Fusaro National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by V A Fusaro in
Google Scholar
PubMed
Close
,
S Ross National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by S Ross in
Google Scholar
PubMed
Close
,
D Johann National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by D Johann in
Google Scholar
PubMed
Close
,
V Rajapakse National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by V Rajapakse in
Google Scholar
PubMed
Close
,
B A Hitt National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by B A Hitt in
Google Scholar
PubMed
Close
,
S M Steinberg National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by S M Steinberg in
Google Scholar
PubMed
Close
,
E C Kohn National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by E C Kohn in
Google Scholar
PubMed
Close
,
D A Fishman National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by D A Fishman in
Google Scholar
PubMed
Close
,
G Whitely National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by G Whitely in
Google Scholar
PubMed
Close
,
J C Barrett National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by J C Barrett in
Google Scholar
PubMed
Close
,
L A Liotta National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by L A Liotta in
Google Scholar
PubMed
Close
,
E F Petricoin 3rd National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by E F Petricoin 3rd in
Google Scholar
PubMed
Close
, and
T D Veenstra National Cancer Institute Biomedical Proteomics Program, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.

Search for other papers by T D Veenstra in
Google Scholar
PubMed
Close

Serum proteomic pattern diagnostics is an emerging paradigm employing low-resolution mass spectrometry (MS) to generate a set of biomarker classifiers. In the present study, we utilized a well-controlled ovarian cancer serum study set to compare the sensitivity and specificity of serum proteomic diagnostic patterns acquired using a high-resolution versus a low-resolution MS platform. In blinded testing sets, the high-resolution mass spectral data contained multiple diagnostic signatures that were superior to the low-resolution spectra in terms of sensitivity and specificity (P<0.00001) throughout the range of modeling conditions. Four mass spectral feature set patterns acquired from data obtained exclusively with the high-resolution mass spectrometer were 100% specific and sensitive in their diagnosis of serum samples as being acquired from either unaffected patients or those suffering from ovarian cancer. Important to the future of proteomic pattern diagnostics is the ability to recognize inferior spectra statistically, so that those resulting from a specific process error are recognized prior to their potentially incorrect (and damaging) diagnosis. To meet this need, we have developed a series of quality-assurance and in-process control procedures to (a) globally evaluate sources of sample variability, (b) identify outlying mass spectra, and (c) develop quality-control release specifications. From these quality-assurance and control (QA/QC) specifications, we identified 32 mass spectra out of the total 248 that showed statistically significant differences from the norm. Hence, 216 of the initial 248 high-resolution mass spectra were determined to be of high quality and were remodeled by pattern-recognition analysis. Again, we obtained four mass spectral feature set patterns that also exhibited 100% sensitivity and specificity in blinded validation tests (68/68 cancer: including 18/18 stage I, and 43/43 healthy). We conclude that (a) the use of high-resolution MS yields superior classification patterns as compared with those obtained with lower resolution instrumentation; (b) although the process error that we discovered did not have a deleterious impact on the present results obtained from proteomic pattern analysis, the major source of spectral variability emanated from mass spectral acquisition, and not bias at the clinical collection site; (c) this variability can be reduced and monitored through the use of QA/QC statistical procedures; (d) multiple and distinct proteomic patterns, comprising low molecular weight biomarkers, detected by high-resolution MS achieve accuracies surpassing individual biomarkers, warranting validation in a large clinical study.

Free access
F M Brouwers
Search for other papers by F M Brouwers in
Google Scholar
PubMed
Close
,
E F Petricoin III
Search for other papers by E F Petricoin III in
Google Scholar
PubMed
Close
,
L Ksinantova
Search for other papers by L Ksinantova in
Google Scholar
PubMed
Close
,
J Breza
Search for other papers by J Breza in
Google Scholar
PubMed
Close
,
V Rajapakse
Search for other papers by V Rajapakse in
Google Scholar
PubMed
Close
,
S Ross
Search for other papers by S Ross in
Google Scholar
PubMed
Close
,
D Johann
Search for other papers by D Johann in
Google Scholar
PubMed
Close
,
M Mannelli
Search for other papers by M Mannelli in
Google Scholar
PubMed
Close
,
B L Shulkin
Search for other papers by B L Shulkin in
Google Scholar
PubMed
Close
,
R Kvetnansky
Search for other papers by R Kvetnansky in
Google Scholar
PubMed
Close
,
G Eisenhofer
Search for other papers by G Eisenhofer in
Google Scholar
PubMed
Close
,
M M Walther
Search for other papers by M M Walther in
Google Scholar
PubMed
Close
,
B A Hitt
Search for other papers by B A Hitt in
Google Scholar
PubMed
Close
,
T P Conrads
Search for other papers by T P Conrads in
Google Scholar
PubMed
Close
,
T D Veenstra
Search for other papers by T D Veenstra in
Google Scholar
PubMed
Close
,
D P Mannion
Search for other papers by D P Mannion in
Google Scholar
PubMed
Close
,
M R Wall
Search for other papers by M R Wall in
Google Scholar
PubMed
Close
,
G M Wolfe
Search for other papers by G M Wolfe in
Google Scholar
PubMed
Close
,
V A Fusaro
Search for other papers by V A Fusaro in
Google Scholar
PubMed
Close
,
L A Liotta
Search for other papers by L A Liotta in
Google Scholar
PubMed
Close
, and
K Pacak
Search for other papers by K Pacak in
Google Scholar
PubMed
Close

Metastatic lesions occur in up to 36% of patients with pheochromocytoma. Currently there is no way to reliably detect or predict which patients are at risk for metastatic pheochromocytoma. Thus, the discovery of biomarkers that could distinguish patients with benign disease from those with metastatic disease would be of great clinical value. Using surface-enhanced laser desorption ionization protein chips combined with high-resolution mass spectrometry, we tested the hypothesis that pheochromocytoma pathologic states can be reflected as biomarker information within the low molecular weight (LMW) region of the serum proteome. LMW protein profiles were generated from the serum of 67 pheochromocytoma patients from four institutions and analyzed by two different bioinformatics approaches employing pattern recognition algorithms to determine if the LMW component of the circulatory proteome contains potentially useful discriminatory information. Both approaches were able to identify combinations of LMW molecules which could distinguish all metastatic from all benign pheochromocytomas in a separate blinded validation set.

In conclusion, for this study set low molecular mass biomarker information correlated with pheochromocytoma pathologic state using blinded validation. If confirmed in larger validation studies, efforts to identify the underlying diagnostic molecules by sequencing would be warranted. In the future, measurement of these biomarkers could be potentially used to improve the ability to identify patients with metastatic disease.

Free access